chrisvoncsefalvay/vaers-outcomes huggingface dataset:
At 8:30 pm on 1/1/2021, I began to have right side pain in my back under rib area. Pain was pretty intense and I took 2 Extra Strength Tylenol 500 mg and went to bed. I had a restless night and pain continued until1:30 pm on 1/2/2021 when it subsided.  I don?t know if it was related to vaccine. I don?t know if it was kidney pain.
Swollen & irritated eyelids. Prescribed erythromicine and caladryl
PT WAS GIVEN 0.5ML INSTEAD OF THE STANDARD DOSE FOR PFIZER OF 0.3ML
Patient passed out within a couple minutes of injection, had seizure like activity, was sweating.  He was alert shortly after. Ambulance came and took the patient
rashes all over her body; This is a spontaneous report from a contactable consumer or other non hcp. A 49-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection, Batch/Lot Number: EWN0171), via an unspecified route of administration on an unspecified date as DOSE 1, SINGLE for covid-19 immunization. Medical history included hypothyroid. The patients concomitant medications were not reported.  The patient experienced rashes all over her body on an unspecified date.She called the hospital and they said that her rashes may be an allergy to one of the ingredients of the vaccine or it's her immune system reacting with the vaccine. She took Zyrtec medication for this side effect. The outcome of event was unknown.   No follow-up attempts are needed. No further information is expected.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 68-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 23Sep2022 at 12:00 as dose 5 (booster), single (Lot number: GH9693) at the age of 67 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Gall bladder removal" (unspecified if ongoing); "Uterine cancer" (unspecified if ongoing); "Obesity" (unspecified if ongoing); "Lymphedema" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant) all with onset Feb2023, outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive. Therapeutic measures were taken as a result of covid-19, drug ineffective.  Clinical information: Other medication in 2 weeks: No. Anti-viral details: Paxlovid, Product: COVID 19 Treatment Brand: Pfizer, Treatment start date: 07Feb2023, Treatment stop date: 12Feb2023, lot number=GF6392, Indication: Treatment of COVID-19.
nerve pain; stabbing pain; spasms; fatigue / is still continuing now.; difficulty going up the stairs; wakes her up at night, and states she feels like "Frankenstein"; This case was reported by a pharmacist via sales rep and described the occurrence of nerve pain in a 56-year-old female patient who received Herpes zoster (Shingrix) (batch number T2CS3, expiry date unknown) for prophylaxis.   Concomitant products included Herpes zoster (Shingrix).   In March 2020, the patient received the 2nd dose of Shingrix. In April 2020, 1 month after receiving Shingrix, the patient experienced nerve pain, pain, spasms, fatigue, mobility decreased and difficulty sleeping. On an unknown date, the outcome of the nerve pain, pain, spasms and fatigue were not recovered/not resolved and the outcome of the mobility decreased and difficulty sleeping were unknown.   It was unknown if the reporter considered the nerve pain, pain, spasms, fatigue, mobility decreased and difficulty sleeping to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. In December 2019, the patient received the 1st dose in left deltoid muscle. In March 2019, the patient received the 2nd dose in left deltoid muscle The patient started experiencing out of the ordinary symptoms one month after receiving her second dose of Shingrix. The symptoms were described as stabbing pain, spasms, nerve pain, fatigue that was still continuing.  She had difficulty going up the stairs, wakes her up at night, and stated she feels like Frankenstein. She has already gone to rheumatologist for a work up and has an appointment with a neurologist soon for another work up.
she accidently gave a patient a dose of  PNEUMOV AX 23 but the patient was ordered and supposed to receive the "Meningococcal vaccine" (unspecified); No additional adverse experiences reported by the patient; This spontaneous report as received from a medical assistant referring to a 17-year-old male patient. The patient's pertinent medical history, drug reactions/allergies, concurrent  conditions and concomitant medications were not reported.       On an unknown date, the patient was accidentally vaccinated a dose of with pneumococcal vaccine, polyvalent (23-valent)(PNEUMOVAX23) 0.5 ml/single dose, lot # T028093 with expiration date 24-APR-2022, for prophylaxis (strength, route of administration and anatomical location were not reported), instead of unspecified meningococcal vaccine(MENINGOCOCCAL VACCINE) (strength, dose, route of administration, anatomical location, lot #, expiration and indication were not reported). No additional adverse experiences were reported by the patient. The reporter stated that she could not verify what vaccine the patient was supposed to receive other than "meningococcal" and did not know the medical history of the patient or if the vaccine would be indicated for the patient at this age due to increased risk of pneumococcal disease. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. devicelotnumber: T028093; expirationdate: 24-APR-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not suggest a causal association with the device or device constituent
pt recv vax;collapsed to floor,struck head, unresponsive for about 4-6 sec;extension of upper extremities;felt weak, had stomachache;to take pt to er;
Dose administer out of age range. Client was 17 years old. No adverse events to report. Clinic refused to administer 2nd dose on 2/11/2021.
Swollen left supraclavicular and left axillary lymph nodes; Swollen left supraclavicular and left axillary lymph nodes; fever; chills; fatigue; headache; body aches; sore muscles/joints; sore muscles/joints; This is a spontaneous report from a contactable other-healthcare professional (patient) reporting herself.  A 27-year-old female non-pregnant patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: EN6199), via intramuscular route of administration in arm left on 05Mar2021 at 15:00 as a 2nd dose, single dose for COVID-19 immunisation. The patient's medical history was reported as none and the patient had known allergies to sulfa and latex. Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: EN6201), via intramuscular in arm left on 12Feb2021 at 13:00 as a 1st dose, single dose for COVID-19 immunisation. Age at vaccination was 27 years and the patient was not pregnant at time of vaccination. The patient's concomitant medications were not reported. Other medications in two weeks included daily multivitamin and oral birth control. It was reported that, no other vaccine in four weeks. No covid prior vaccination and no covid tested post vaccination. On 06Mar2021 at 05:00 AM, the patient experienced swollen left supraclavicular and left axillary lymph nodes, fever, chills, fatigue, headache, body aches and sore muscles/joints. Treatment was not received for the events. The outcome of the events was recovering.  No follow-up attempts are possible. No further information is expected.
Information has been received from a 26 year old female consumer, who was vaccinated with the first dose, 0.5ml, IM, of Gardasil (Lot # not provided, date unspecified), and had unknowingly become pregnant, estimated date of conception, 22-MAY-2007 (on 19-JUN-2007, she was "4 weeks pregnant"). On 04-JUN-2007, she was vaccinated with the second dose, 0.5ml, of Gardasil (Lot # not provided). There was no concomitant medication, and no other pertinent medical history. On 19-JUN-2007, she reported a pregnancy test had confirmed her pregnancy. The estimated date of delivery was 28-FEB-2008. The consumer confirmed that she has had no ill effects. Follow up information received from a physician's office, indicated that this was the patient's first pregnancy, and added that she was a tobacco user. On 03-JUL-2007 through 08-JUL-2007, she was treated for gout, with prednisone, 5mg (no other details provided). On 10-JUL-2007, a pregnancy ultrasound was normal. The were no other illnesses or infections during pregnancy. On 10-DEC-2007, the patient underwent an ultrasound due to decreased fetal movement, and it was determined that the infant had severe intrauterine growth retardation (IUGR). It was also determined that the patient had placental insufficiency. Lab testing revealed the mother was positive for methylene-tetra-hydro-folate reductase (MTHFR) mutation homozygous and included cardiolipin ob and lupus anticoagulant testing (results not provided). The patient was diagnosed with antiphospholipid syndrome. An "emergent classical" caesarean section was performed, resulting in the live birth of a male infant, weight 700 gm, Apgar score 4/8. On 12-DEC-2007, the infant died, due to complications from prematurity. An autopsy on the infant was pending. The outcome of gout. MTHFR homozgous and antiphopholipid syndrome was unknown. Additional information has been requested.
Pt states site of Varicella inj started itching 6/30 and it started swelling at site. Nurse noted redness and swelling and heat at site on 7/1/10 and pt cont. to c/o itching. By 7/20 pt states was much worse, a hard knot developed and redness was progressing all around arm and very uncomfortable.
After injection, during 15 minute observation, member c/o faint like feeling, became pale. Mom states child did not eat breakfast or dinner the night prior. Child placed on stretcher and vital signs monitored. Provided juice and graham crackers. Dr notified. Member improved.
I was running a fever, took a home COVID-19 test that came back negative. The next day I still had a fever, so I decided to go to urgent care and get a COVID-19 test and it came back positive. I asked about getting a prescription for PAXLOVID, the doctor was wary about prescribing for fear of me getting rebound COVID-19. Once I got home, I called my regular PCP who prescribed the PAXLOVID, my fever broke overnight. I am now feeling better with the exception of a dry lingering cough.
Erythema, papular lesions, some vesicular with erythema base, on face and trunk. She has increased in number, over the past 2 days.
Patient presented to health center with left upper arm red, warm to touch and tender to touch where immunization was given on 6/11/19. Patient reports that the night the injection was given her arm was lame, but was not red and tender until this morning, 6/13/19. Patient seen by a provider 6/13/19 advised cool compresses and Benadryl as needed.
ACHING PAIN IN FEET, ANKLES, LEGS, JOINTS ACHED IN KNEES & ANKLES, SKIN UNCOMFORTABLE TO TOUCH, NO FEVER, NO RASH, AND MUCH IMPROVED TODAY 7/11/2011. CLIENT HAS DOCTOR VISIT ON 7-12-2011.
6 days after vaccinations, pt developed fever and rash. Fever reached 102.5 with Tylenol. Parent phoned on 2-4-04 to report that the patient continued to display a rash which was worsening and changing in characteristics. Rash began as a macular pink rash and by 2-3-04 had spread and was now "red and bumpy." Mom stated child had been hospitalized after receiving varicella vaccine (date unavailable)- 4 hours post-vaccination
Vaccine administered at 1:50 pm. After 15 minute wait time felt itching in arms, elbow, upper back, and a metallic taste in mouth, muscle tightness in upper right back and neck. Blood pressure reading of 120/80. Consulted anaphylactic protocols administered 25 mg Benadryl PO at 2:34pm.  Asked client to wait another 30 minutes at vaccination site for monitoring. 3:30 pm rechecked BP 120/90, client reports feeling better. Itching has subsided and was able to leave clinic. Reviewed signs and symptoms to monitor for and when to seek medical attention. Also recommended speaking to primary care provider before receiving second dose of vaccine.
no adverse affects reported; patients received doses of improperly stored Varivax; This spontaneous report was received from a health professional and refers to a patient of unknown gender and age. The patient's concurrent conditions, medical history, concomitant therapies, drug reaction and allergies were not reported.   On an unknown date in April 2019 (reported as 25-APR-2019 or 26-APR-2019), the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck)(VARIVAX) subcutaneously, lot # R034396, expiration date 27-NOV-2020, (dose was not reported) for prophylaxis. Administered dose of vaccine experienced the temperature excursion of 38 degrees Fahrenheit for 72 hours. Sterile diluent was stored properly. There were no previous excursions reported. Data logger was not involved. No adverse effects was reported.  This is one of eleven reports from the same reporter.; Sender's Comments:  US-009507513-1904USA013210: US-009507513-1904USA013270: US-009507513-1904USA013268: US-009507513-1904USA013265: US-009507513-1904USA013269: US-009507513-1904USA013275: US-009507513-1904USA013276: US-009507513-1904USA013278: US-009507513-1904USA000187: US-009507513-1904USA000191:
Painful injection site later the same day.  Following morning injection site very painful/sore. Headache. Fever.
Standard reaction like a flu; A little fever; Headache; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Standard reaction like a flu), PYREXIA (A little fever) and HEADACHE (Headache) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007C21A) for COVID-19 vaccination.     The patient's past medical history included Cancer from 2016 to 2017. Concurrent medical conditions included Neck discomfort (25 years ago), Arthritis (15 years ago) and Scoliosis (since birth). Concomitant products included IBUPROFEN for Neck discomfort, ACYCLOVIR [ACICLOVIR] for an unknown indication.    On 22-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Apr-2021, the patient experienced INFLUENZA LIKE ILLNESS (Standard reaction like a flu), PYREXIA (A little fever) and HEADACHE (Headache). The patient was treated with IBUPROFEN for Headache, at an unspecified dose and frequency. On 23-Apr-2021, INFLUENZA LIKE ILLNESS (Standard reaction like a flu), PYREXIA (A little fever) and HEADACHE (Headache) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Other vaccines given within 1 month prior to Moderna COVID-19 vaccine  chicken pox vaccine around both fist.  Patient taking Acyclovir since 24 years ago.  Other concomitant medication include vitamins.     This case was linked to MOD-2022-495240, MOD-2022-495241 (Patient Link).
tested positive for Covid; tested positive for Covid; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 63-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 04Apr2021 as dose 1, single (Lot number: EW0150), on 25Apr2021 as dose 2, single (Lot number: EW0170), on 14Nov2021 as dose 3 (booster), single (Lot number: FH8028) and on 20Apr2022 as dose 4 (booster), single (Lot number: FJ4991) for covid-19 immunisation. The patient's relevant medical history included: "known allergies penicillin" (unspecified if ongoing), notes: known allergies penicillin. Concomitant medication(s) included: LEVOTHYROXINE; ALENDRONATE. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 10Jun2022, outcome "recovering" and all described as "tested positive for Covid". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 antibody test: (10Jun2022) Positive, notes: 10Jun tested positive for Covid; (19Jun2022) Negative, notes: Tested negative on 19Jun; (21Jun2022) Positive, notes: Tested positive 21Jun; (24Jun2022) Positive, notes: 24Jun (again positive test). Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical Course: The patient received Levothyroxine and Alendronate within 2 weeks of the vaccination. It was reported that the on 10Jun2022, the patient tested positive for Covid, started Paxlovid in PM and concluded 15Jun AM. The patient tested negative on 19Jun. The symptoms were not fully resolved though and returned more strongly than before. The patient tested positive 21Jun2022. The strong flu-like symptoms persisted through today 24Jun22 (again positive test) but feeling a bit better now. All were in home antigen testing.    No follow-up attempts are possible. No further information is expected.
pt arm was bothering him;the area of inj was warm, swollen, reddened, & tender;
To ED on 2/2/2022 with increased cough and dyspnea. States "weak and can't breathe." On home O2 @ 2L. O2 sats now upper 80's on 6 L. ABGs on 2 L show pO2 55 and pCO2 42. Placed on venti-mask. Admit. Code on 2/3-pt in V Tach that progressed to PEA. Code called.
Pain and redness at site of PPSV23 from 7/9/18. Pt states lump did not appear until today.
Swollen lymph node moves and it is size of lima bean/Swollen lymph node above collar bone; This spontaneous case was reported by a consumer and describes the occurrence of LYMPHADENOPATHY (Swollen lymph node moves and it is size of lima bean/Swollen lymph node above collar bone) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Drug allergy (Allergic to Erythromycin).    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Mar-2021, the patient experienced LYMPHADENOPATHY (Swollen lymph node moves and it is size of lima bean/Swollen lymph node above collar bone). At the time of the report, LYMPHADENOPATHY (Swollen lymph node moves and it is size of lima bean/Swollen lymph node above collar bone) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient stated that she was evaluated by her physician.  Patient stated that her physician recommends the COVID-19 vaccination.
My Father suffered a stroke approximately 5 weeks after his last COVID booster.  He has always been a healthy man and we suspect that his recent booster shot  may have caused his stroke.
This spontaneous report as received from a registered nurse refers to an unspecified number of patients of unknown age and unknown gender. Pertinent medical history, drug reactions or allergies were unspecified. On an unknown date an unspecified number of patients were vaccinated with improperly stored M-M-R II, exposed to 33 F for 6 days (144 hours), (dose, dose schedule, route, anatomical location, lot number and expiration date were unspecified). No adverse effects were reported. No concomitant therapies were reported. The outcome of the event was unknown. This is one of several reports received from the same reporter. Additional information has been requested.
Within 1 week of receiving Covid Vaccine, patient developed extreme lethargy, severe shortness of breath, lightheadedness at times, oral sores and swollen gums, dysphagia. At 3 months out now, all symptoms have continued with no signs of improvement.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter (Consumer or other non HCP). The reporter is the patient.  A 61-year-old female patient (not pregnant) received BNT162b2 (PFIZER BIONTECH COVID-19 VACCINE), on 26Mar2021 as dose 1, single (Lot number: ER8730), in left arm, on 16Apr2021 as dose 2, single (Lot number: EW0153), in left arm, on 13Nov2021 as dose 3 (booster), single (Lot number: FG3527), in left arm and on 10Apr2022 as dose 4 (booster), single (Lot number: FK9893) at the age of 61 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Factor V Leiden" (unspecified if ongoing); "Known allergies: Sulfa drugs" (unspecified if ongoing). Concomitant medications included: WARFARIN; SERTRALINE; SUMATRIPTAN. Past drug history included: Percocet, reaction: "Known allergies: Percocet"; Anticoagulation, notes: long-term anticoagulation treatment. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Jul2022) Negative; (Jul2022) Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19 and included treatment with Paxlovid. Clinical course: After completion of full 5 day Paxlovid regimen and symptoms mostly resolved/neg test, symptoms reemerged 4 days later and tested positive.
After my first dose of the Pfizer Covid vaccine I noticed my heart beginning to race uncontrollably and I would get slightly lightheaded. I was thinking okay I'll wait awhile and see if it goes away but it never did and then the 2nd dose of the vaccine made it worse to the point of me feeling like I was going to pass out from time to time. I am now under the care of a cardiologist for this issue.   First Dose of Pfizer: 3/31/2021 (EP6955) unsure of the exact time but my fiance and I think it was at 10:00 or 11:00am (After the vaccine my fiance had heart issues as well and was at risk for myocarditis. Neither one of us has felt well since this vaccine and felt way worse after the second.    Second Dose of Pfizer: 4/27/2021 (ER8731) 6:10pm
pt recvd vax; exp weakness in arm difficulty lifting & doing usual activities; pain also, but not too severe; 17dec93 no response to f/u request;
Pt was here for a WCC and needed her 11 yrs vaccines pt was doing fine during the procedure was left in the room for observation for 15 mins when pt was going to be discharged but began with intense headache and lightheadedness Provider was notified and provider came back to exam patient. Ibuprofen was and 15 minutes after all symptoms were resolved. Provider followed up with mother the next day and stated that patient was doing well. (Weight: 127 lbs).